Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21343961 | 0.82 | MIF (0.36) | ALDH1A1 | |
| SCHEMBL21344401 | 0.78 | GPR119 (0.52) | GPR119AREGLN2ALDH1A1MEN1 | |
| SCHEMBL21343962 | 0.77 | RAB9A (0.35) | RAB9AKMT2A | |
| SCHEMBL21343948 | 0.77 | GPR119 (0.48) | GPR119AREGLN2IRAK4MAPK1 | |
| SCHEMBL21343229 | 0.77 | MEN1 (0.35) | MEN1RAB9AMDM2KMT2A | |
| SCHEMBL21344273 | 0.75 | RORC (0.35) | — | |
| SCHEMBL3146175 | 0.71 | GPR119 (0.60) | GPR119 | |
| SCHEMBL2075207 | 0.71 | MEN1 (0.45) | ALDH1A1MEN1KMT2ANPSR1PREP | |
| SCHEMBL5504994 | 0.71 | KLK7 (0.47) | GPR119JAK2JAK1KLK7KLK5 | |
| SCHEMBL8112498 | 0.70 | GPR119 (0.52) | GPR119AREGLN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399262-A1 | COMPOUNDS FOR INHIBITING PROTEIN DEGRADATION AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER | PI THERAPEUTICS LTD (IL) | 2020-12-24 | — | — | US | disclosed |
| WO-2019171379-A1 | COMPOUNDS FOR INHIBITING PROTEIN DEGRADATION AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER | PI THERAPEUTICS LTD. (IL) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399262-A1 | COMPOUNDS FOR INHIBITING PROTEIN DEGRADATION AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER | ATG7, SQSTM1, UBQLN1 | GPR119 3596/4885AR 2930/4885EGLN2 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.